AstraZeneca Pharmaceuticals Inc. filed a motion on Wednesday to block Dr. Christopher Reist from testifying for Handa Pharmaceuticals LLC, a rival pharmaceutical company, in an ongoing patent infringement case over AstraZeneca’s Seroquel XR®. Dr. Reist worked on the clinical trials for Seroquel XR® between 2001 and 2007 as one of it’s paid speakers. Handa has selected Dr. Reist as an expert witness in the infringement case, something AstraZeneca states will create a conflict of interest. AstraZeneca is represented by Finnegan.
Commentary
Patent Strategy Could Shape Financing, Valuation and Risk in Offshore Energy Projects
June 30, 2026
Award/Ranking
Finnegan’s European Practices and Attorneys Highlighted in 2026 Managing IP Rankings
June 25, 2026
Press Release
BMW Obtains Preliminary Injunction Against Zync; Federal Court Orders Zync to Halt ITC Trade Secret
June 23, 2026
Award/Ranking
Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers
June 22, 2026
Commentary
U.S. Judge Rules Forum-Selection Clause Bars Zync from Pursuing ITC Trade Secret Case
June 15, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.